2017;1599:25-42. doi: 10.1007/978-1-4939-6955-5_3.

Author information

1
Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
2
Inserm U830, Institut Curie - Section de Recherche, 26 rue d'Ulm, cedex 5, Paris, 75248, France.
3
Service de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, 26 rue d'Ulm, cedex 5, Paris, 75248, France.
4
Inserm U830, Institut Curie - Section de Recherche, 26 rue d'Ulm, cedex 5, Paris, 75248, France. Marc-Henri.Stern@curie.fr.

Abstract

Ataxia Telangiectasia (A-T) is caused by biallelic inactivation of the Ataxia Telangiectasia Mutated (ATM) gene, due to nonsense or missense mutations, small insertions/deletions (indels), splicing alterations, and large genomic rearrangements. After establishing A-T clinicaldiagnosis, a molecular confirmation is needed, based on the detection of one of these loss-of-function mutations in at least one allele. In most cases, the pathogenicity of the detected mutations is sufficient to make a definitive diagnosis. More rarely, mutations of unknown consequences are identified and direct biological analyses are required to establish their pathogenic characters. In such cases, complementary analyses of ATM expression, localization, and activity allow fine characterization of these mutations and facilitate A-T diagnosis. Here, we present genetic and biochemical protocols currently used in the laboratory that have proven to be highly accurate, reproducible, and quantitative. We also provide additional discussion on the critical points of the techniques presented here.

KEYWORDS:

DNA sanger sequencing; Functional assays; MLPA

PMID:
 
28477109
 
DOI:
 
10.1007/978-1-4939-6955-5_3
[Indexed for MEDLINE]